Navigation Links
50,000 Potassium Iodide Pills Donated to Japan
Date:3/15/2011

MOORESVILLE, N.C., March 15, 2011 /PRNewswire/ -- Approximately 50,000 potassium iodide tablets have been donated by Nukepills.com to Tokushukai Hospital in Tokyo, Japan for immediate distribution to those affected by Japan's nuclear reactor crisis. This effort was facilitated by Dr. Alisa Suzuki Han, Radiologist at Brigham and Women's Hospital, a teaching facility of Harvard Medical School, in Boston, MA. The radiation-blocking drug, currently en route to Japan, will be distributed by the Tokushukai Medical Aid Team. "We are very pleased that these tablets will be given to people directly affected by the nuclear crisis," stated Troy Jones, President of Nukepills.com. "The efforts of Dr. Han and the Tokushukai Medical Aid Team are a wonderful example of professionals coming together to ensure the health and livelihood of those most in need."

Stockpiling of potassium iodide is recommended by health officials worldwide to prevent thyroid cancer of those exposed to radioactive iodine in the event of a nuclear reactor accident or detonation of a nuclear bomb. FDA approved in 1982, potassium iodide is available without a prescription. More information about FDA approved potassium iodide can be found online at http://www.nukepills.com.

Nukepills.com, celebrating its 12th year in business, is an Internet-based supplier of radiation emergency preparedness products that protect against dirty bomb radiation, nuclear reactor accidents and nuclear weapon fallout, and are used for radiation therapy/decontamination in hospitals. The company was founded in 1999 as a means of supplying FDA approved Iosat(TM) Potassium Iodide directly to the general public and now has international sales programs throughout Canada, Europe, Asia and the Middle East. In early 2009, Nukepills.com sold 5.4 million doses of FDA approved ThyroShield(TM) Liquid Potassium Iodide to Kuwait's Ministry of Health and expects Government Emergency Preparedness grants and civilian orders to continue to drive sales of all of its products well into 2011.

Logo: http://www.ereleases.com/pic/Nukepills-logo.jpg Contact: Troy Jones, President, Nukepills.comPh: 866-283-3986info@nukepills.com 631 Brawley School Rd STE 407Mooresville, NC 28117http://www.nukepills.com Twitter: http://twitter.com/nukepills This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE Nukepills.com
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Will Rogers Institute Awards Top Doctor $50,000 for Outstanding Contributions to Lung Research
2. PharmAthene Receives Four Therapeutic Discovery Project Grants Totaling Approximately $850,000
3. $250,000 Awarded to Smartfield, Inc. of Lubbock, TX by the Texas Emerging Technology Fund
4. BioMed Realty Trust Expands Lease With Ironwood Pharmaceuticals for 50,000 Square Feet in Cambridge, Massachusetts
5. Intralink-Spine Inc. Awarded $750,000 Small Business Innovation Research Phase II Grant
6. March of Dimes Awards $250,000 Prize to Scientist Who Discovered How to Reprogram Human Cells
7. Corgenix Secures $1,750,000 Asset Based Credit Facility Representing Initial Gross Proceeds of $1.109 Million
8. Collexis BiomedExperts Fast Approaching 150,000 Registered Users
9. ZINO Society Spurring Investments, 12 Life Sciences Companies to Vie for $50,000 ZINO Life Fund
10. Huntington Area Development Council Attracts Technology-Based Startup Companies With $150,000 Grant From Verizon West Virginia
11. NeoStem Secures $250,000 in an Above Market Financing and Expands Its Relationship With New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , ... December 01, 2016 , ... ACEA Biosciences, Inc. ... Phase I/II clinical trials for AC0010 at the World Conference on Lung Cancer 2016, ... an update on the phase I/II clinical trials for AC0010 in patients with advanced ...
(Date:12/2/2016)... ... 2016 , ... PhUSE will build on the huge success ... Day Events (SDE) to organize a multiple-day US conference. The first annual US ... the pharmaceutical and life sciences industry will cover industry standards, data science, regulations ...
(Date:12/2/2016)... IL (PRWEB) , ... December 01, 2016 , ... ... to congratulate long-term client Nanowear on their recent FDA Class II 510(k) clearance ... cleared a significant hurdle in commercializing remote cardiac monitoring devices that rely on ...
(Date:12/2/2016)... NEW YORK , Dec. 1, 2016   ... liquid photopurification, announced today that the Company has concluded ... has the right for a 90-day period to acquire ... invoice value of approximately USD 3.7 million.  ... an agreement with Tamarack under which Tamarack will seek ...
Breaking Biology Technology:
(Date:6/27/2016)... 27, 2016 Research and Markets has announced ... report to their offering. ... to grow at a CAGR of 12.28% during the ... on an in-depth market analysis with inputs from industry experts. The ... coming years. The report also includes a discussion of the key ...
(Date:6/20/2016)... , June 20, 2016 Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... prisons involved, it has secured the final acceptance ... facilities for Managed Access Systems (MAS) installed. Furthermore, ... facilities to be installed by October, 2016. MAS ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
Breaking Biology News(10 mins):